"Men"

The development of an effective anti-aging drug and functional food to slow down ASCs' aging is crucial

As medicine continues to advance, there are many good drugs and options to fight cancer. Just recently, a study showed that the NALIRIFOX regimen significantly improved the overall survival of patients with advanced pancreatic ductal adenocarcinoma who had not received previous treatment.

Warning: If you have 4 symptoms in your eye, don't take them seriously, they are precursors to retinal detachment

Prior to the granting of marketing authorisation by the MHRA, Biyze® had been approved by the European Commission for a number of indications and is currently the only drug approved for the treatment of MZL in Great Britain.

Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have now identified a new treatment that promises to help cancer patients with bone marrow transplants manage side effects better than current standard therapies, making the treatment more effective and safer.

This is the best way to prevent blood clots.

Nasopharyngeal cancer is a very complex disease that causes abnormal symptoms in the ears and nose, which can seriously affect the health and living conditions of patients with nasopharyngeal cancer.

Every September is the "World Alzheimer's Disease Month". In 2022, the theme of "World Alzheimer's Disease Month" is "Know Dementia, Know Alzheimer's - Another, we can do so much". It aims to continue to focus on early screening and early diagnosis, and focus on publicizing the 10 early symptoms, 12 risk factors that can be intervened and medical and social support after diagnosis of Alzheimer's disease, so as to achieve the goal of overall management of Alzheimer's disease

To prevent dry skin, roughness and constipation, you should also pay attention to diet and nutrition. Vitamin A has the role of promoting epithelial growth and protecting the skin, so eat more carrots and green leafy vegetables and beans containing vitamin A in autumn.

According to data from a phase 2 trial, the new treatment Tovorafenib resulted in significant tumour shrinkage in 64% of patients with low-grade gliomas in children, a clinical benefit rate of 91%.